Aspectos moleculares de la acción antineoplásica de la vitamina D
Palabras clave:
cáncer, calcitriol, mecanismos moleculares, efectos antineoplásicosResumen
Los factores ambientales, en particular los dietarios, pueden influir en el desarrollo y la prevención del cáncer. La vitamina D (colecalciferol) ha sido por años asociada a la regulación de la homeostasis de calcio pero existen numerosos estudios epidemiológicos, bioquímicos y genéticos sobre otros efectos no clásicos de la vitamina D, como el desarrollo y la progresión de diferentes cánceres. El objetivo del presente artículo es brindar una revisión sobre los mecanismos moleculares de la acción antineoplásica de la vitamina D. Estos efectos no están completamente establecidos pero se sabe que la vitamina D induce el arresto del ciclo celular, desencadena vías apoptóticas, inhibe la angiogénesis y altera la adhesión celular. Mantener niveles adecuados de vitamina D son necesarios para una gran cantidad de procesos fisiológicos y no solamente para el mantenimiento de la homeostasis del hueso. Los estudios clínicos podrían determinar niveles de vitamina D que puedan proteger también contra el desarrollo del cáncer.
Descargas
Los datos de descargas todavía no están disponibles.
Citas
Lichtenstein, P, Holm, N, Verkasalo, P, Iliadou A, Kaprio J, Koskenvuo, M, Pukkala E, Skytthe A, and Hemminki, K: Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark and Finland. N England J Med; 2000, 343: 78-85.
Lin, R, White, JH: The pleitropic actions of vitamin D. Bio Essays; 2003, 26: 21-28. 3.
Bickle, D: Nonclassic actions of vitamin D. J Clin Endocrinol Metab; 2009, 94: 26-34. 4.
De Luca, HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr; 2004, 74: 494-500.
Ali, MM, Vaidya, V: Vitamin D and cancer. J Cancer Res Ther; 2007, 3: 225-230.
Feskanich, D, Ma, J, Fuchs, CS, Kirkner, GJ, Hankinson, SE, Hollis, BW, Giovannucci, EL: Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev; 2004, 13: 1502-1508.
Abbas, S, Chang-Claude, J, Linseisen, J: Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer; 2009,124: 250-255.
Blackmore, KM, Lesosky, M, Barnett, H, Raboud, JM, Vieth, R, Knight, JA: Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol; 2008,168: 915-924.
Garland, CF, Mohr, SB, Gorham, ED, Grant, WB, Garland, FC: Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med; 2006, 31: 512-514.
Bouillon, R, Eelen, G, Verlinden, L, Mathieu, C, Carmeliet, G, Verstuyf, A: Vitamin D and cancer. J Steroid Biochem Mol Biol; 2006, 102: 156-162.
Bikle, D: What is new in vitamin D: 2006-2007. Curr Opin Rheumatol; 2007, 19: 383-388.
Demay, MB: Mechanisms of vitamin D receptor action. Ann NY Acad Sci; 2006, 1068: 204-213.
Ingraham, BA, Bragdon, B, Nohe, A: Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin; 2008, 24: 139-149. -20- 14.
Welsh, J: Targets of vitamin D receptor signaling in the mammary gland. J Bone Min Res; 2007, 22: 86-89.
Johnson, CS, Muindi, JR, Hershberger, PA, Trump, DL: The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res; 2006, 26: 2543-2549.
Maruyama, R, Aoki, F, Toyota, M, Sasaki, Y, Akashi, H, Mita, H, Suzuki, H, Akino, K, Ohe-Toyota, M, Maruyama, Y, Tatsumi, H, Imai, K, Shinomura, Y, Tokino T: Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res; 2006, 66: 4574-4583.
Welsh, J:Vitamin D and breast cancer: insights from animal models. American Journal of Clinical Nutrition; 2004, 80: 1721S-1724S.
Marchionatti, AM, Picotto, G, Narváez, CJ, Welsh, J, Tolosa de Talamoni, N: Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J Steroid Mol Biol; 2009, 113: 227-232.
Palmer, HG, Gonzalez-Sancho, JM, Espada, J, Berciano, MT, Puig, I, Baulida, J, Quintanilla, M, Cano, A, de Herreros, AG, Lafarga, M, Muñoz, A.: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol; 2001, 154: 369-387.
Campbell, MJ, Gombart, AF, Kwok, SH, Park, S, Koeffler, HP: The antiproliferative effects of 1,alpha- 25(OH)2D3 on breast and cancer cells are associated with induction of BCRA1 gene expression. Oncogene; 2000, 19: 5091-5097. .
Shah, S, Islam, MN, Dakshanumurthy, S, Rizvi, I, Rao, M, Herrell, R, Zinser, G, Valrance, M, Aranda, A, Moras, D, Norman, A, Welsh, J, Byers, S,W: The molecular basis of vitamin D receptor and beta-catenin cross regulation. Mol Cell; 2006, 281: 39114-39120.
Dhawan, P, Wieder, R, Christakos, S: CCAAT enhancer-binding protein alpha is a molecular target for 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. J Biol Chem; 2009, 284: 3086-3095. 23.
Yin, J, Pollock, C, Tracy, K, Chock, M, Martin, P, Oberst, M, Kelly, K: Activation of the RalGEF/Rak pathway promotes prostate cancer metastasis to bone. Mol Cell Biol; 2007, 27: 7538-7550.
Freake, HC, Abeyasekera, G, Iwasaki, J, Marcocci, C, MacIntyre, I, McClelland, RA, Skilton, RA, Easton, DF, Coombes, RC. Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res; 1984, 44: 1677-1681.
Schwartz, G: Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev; 2008, 17: 478-483.
Schöndorf, T, Eisberg, C, Wassmer, G, Warm, M, Becker, M, Rein, DT, Göhring, UJ: Association of the vitamin D receptor genotype with bone metastases in breast cancer patients. Oncology; 2003, 64: 154-159.
Garland, CF, Gorham, ED, Mohr, SB, Grant, WB, Giovannucci, EL, Lipkin, M, Newmark, H, Holick, MF, Garland, FC.: Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol; 2007, 103: 708-711.
Murillo, G, Matusiak, D, Benya, RV, Mehta, RG: Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol;
Lin, R, White, JH: The pleitropic actions of vitamin D. Bio Essays; 2003, 26: 21-28. 3.
Bickle, D: Nonclassic actions of vitamin D. J Clin Endocrinol Metab; 2009, 94: 26-34. 4.
De Luca, HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr; 2004, 74: 494-500.
Ali, MM, Vaidya, V: Vitamin D and cancer. J Cancer Res Ther; 2007, 3: 225-230.
Feskanich, D, Ma, J, Fuchs, CS, Kirkner, GJ, Hankinson, SE, Hollis, BW, Giovannucci, EL: Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev; 2004, 13: 1502-1508.
Abbas, S, Chang-Claude, J, Linseisen, J: Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer; 2009,124: 250-255.
Blackmore, KM, Lesosky, M, Barnett, H, Raboud, JM, Vieth, R, Knight, JA: Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol; 2008,168: 915-924.
Garland, CF, Mohr, SB, Gorham, ED, Grant, WB, Garland, FC: Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med; 2006, 31: 512-514.
Bouillon, R, Eelen, G, Verlinden, L, Mathieu, C, Carmeliet, G, Verstuyf, A: Vitamin D and cancer. J Steroid Biochem Mol Biol; 2006, 102: 156-162.
Bikle, D: What is new in vitamin D: 2006-2007. Curr Opin Rheumatol; 2007, 19: 383-388.
Demay, MB: Mechanisms of vitamin D receptor action. Ann NY Acad Sci; 2006, 1068: 204-213.
Ingraham, BA, Bragdon, B, Nohe, A: Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin; 2008, 24: 139-149. -20- 14.
Welsh, J: Targets of vitamin D receptor signaling in the mammary gland. J Bone Min Res; 2007, 22: 86-89.
Johnson, CS, Muindi, JR, Hershberger, PA, Trump, DL: The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res; 2006, 26: 2543-2549.
Maruyama, R, Aoki, F, Toyota, M, Sasaki, Y, Akashi, H, Mita, H, Suzuki, H, Akino, K, Ohe-Toyota, M, Maruyama, Y, Tatsumi, H, Imai, K, Shinomura, Y, Tokino T: Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res; 2006, 66: 4574-4583.
Welsh, J:Vitamin D and breast cancer: insights from animal models. American Journal of Clinical Nutrition; 2004, 80: 1721S-1724S.
Marchionatti, AM, Picotto, G, Narváez, CJ, Welsh, J, Tolosa de Talamoni, N: Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J Steroid Mol Biol; 2009, 113: 227-232.
Palmer, HG, Gonzalez-Sancho, JM, Espada, J, Berciano, MT, Puig, I, Baulida, J, Quintanilla, M, Cano, A, de Herreros, AG, Lafarga, M, Muñoz, A.: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol; 2001, 154: 369-387.
Campbell, MJ, Gombart, AF, Kwok, SH, Park, S, Koeffler, HP: The antiproliferative effects of 1,alpha- 25(OH)2D3 on breast and cancer cells are associated with induction of BCRA1 gene expression. Oncogene; 2000, 19: 5091-5097. .
Shah, S, Islam, MN, Dakshanumurthy, S, Rizvi, I, Rao, M, Herrell, R, Zinser, G, Valrance, M, Aranda, A, Moras, D, Norman, A, Welsh, J, Byers, S,W: The molecular basis of vitamin D receptor and beta-catenin cross regulation. Mol Cell; 2006, 281: 39114-39120.
Dhawan, P, Wieder, R, Christakos, S: CCAAT enhancer-binding protein alpha is a molecular target for 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. J Biol Chem; 2009, 284: 3086-3095. 23.
Yin, J, Pollock, C, Tracy, K, Chock, M, Martin, P, Oberst, M, Kelly, K: Activation of the RalGEF/Rak pathway promotes prostate cancer metastasis to bone. Mol Cell Biol; 2007, 27: 7538-7550.
Freake, HC, Abeyasekera, G, Iwasaki, J, Marcocci, C, MacIntyre, I, McClelland, RA, Skilton, RA, Easton, DF, Coombes, RC. Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res; 1984, 44: 1677-1681.
Schwartz, G: Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev; 2008, 17: 478-483.
Schöndorf, T, Eisberg, C, Wassmer, G, Warm, M, Becker, M, Rein, DT, Göhring, UJ: Association of the vitamin D receptor genotype with bone metastases in breast cancer patients. Oncology; 2003, 64: 154-159.
Garland, CF, Gorham, ED, Mohr, SB, Grant, WB, Giovannucci, EL, Lipkin, M, Newmark, H, Holick, MF, Garland, FC.: Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol; 2007, 103: 708-711.
Murillo, G, Matusiak, D, Benya, RV, Mehta, RG: Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol;
Descargas
Publicado
2020-02-14
Cómo citar
1.
Bohl LP, Liaudat AC, Picotto G, Tolosa de Talamoni NG. Aspectos moleculares de la acción antineoplásica de la vitamina D. Rev Fac Cien Med Univ Nac Cordoba [Internet]. 14 de febrero de 2020 [citado 1 de mayo de 2024];65(1):16-21. Disponible en: https://revistas.unc.edu.ar/index.php/med/article/view/27686
Número
Sección
Revisiones de literatura
Licencia
La Revista de la Facultad de Ciencias Médicas de Córdoba (RFCM) adhiere a la política de Acceso Abierto y no cobra cargos a los autores para publicar, ni tampoco a lectores para acceder a los artículos publicados.
